ProKidney Corp (PROKN)
XMEX 
Summary
ProKidney: Slow-Burning 'Buy' Opportunity Based On 2027 Approval Of Kidney Disease Therapy
I rate ProKidney a buy due to promising Phase 2 data for rilparencel in advanced CKD, strong FDA alignment, and sufficient cash runway. PROK's Phase 3 PROACT 1 study uses eGFR slope as a surrogate endpoint, with topline data expected in Q2 2027 and potential for accelerated approval. The company halted its second Phase 3 trial, saving over $150m, and expects positive REGEN-007 results to be presented at ASN Kidney Week in November.
PROKIDNEY CP (PROK) Upgraded to Strong Buy: What Does It Mean for the Stock?
PROKIDNEY CP (PROK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
ProKidney Corp. (PROK) is a Great Momentum Stock: Should You Buy?
Does ProKidney Corp. (PROK) have what it takes to be a top stock pick for momentum investors? Let's find out.
ProKidney Corp Profile
| Biotechnology Industry | Healthcare Sector | Bruce Culleton CEO | XMEX Exchange | US74291D1046 ISIN |
| US Country | 204 Employees | - Last Dividend | - Last Split | 12 Jul 2022 IPO Date |
Overview
ProKidney Corp. is a pioneering entity in the biotechnology sector, focusing its efforts on the advancement of cell therapy platforms aimed at the amelioration of chronic kidney diseases. With its inception in 2015, the company has dedicated itself to developing innovative therapeutic solutions from its headquarters in Winston-Salem, North Carolina, USA. The primary mission of ProKidney Corp. is to introduce groundbreaking treatments that offer hope and improved outcomes for patients suffering from various kidney ailments, leveraging the vast potential of cell therapy technologies.
Products and Services
- Renal Autologous Cell Therapy (REACT):
This flagship product embodies the core of ProKidney Corp.'s innovative approach towards tackling chronic kidney diseases. REACT is a cutting-edge therapeutic modality based on the use of autologous homologous cell admixtures. This treatment has successfully completed its Phase I clinical trial, targeting patients with Congenital Anomalies of the Kidney and Urinary Tract (CAKUT). Building upon this initial success, REACT has progressed to Phase III and Phase II clinical trials for addressing moderate to severe diabetic kidney disease, highlighting its potential as a transformative solution for a widespread and impactful health challenge.
Contact Information
